Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 7
1979 6
1980 2
1981 12
1982 13
1983 23
1984 18
1985 35
1986 44
1987 37
1988 41
1989 72
1990 61
1991 87
1992 73
1993 91
1994 84
1995 89
1996 119
1997 147
1998 202
1999 163
2000 254
2001 225
2002 318
2003 291
2004 310
2005 310
2006 350
2007 365
2008 373
2009 436
2010 463
2011 516
2012 498
2013 549
2014 575
2015 641
2016 661
2017 724
2018 682
2019 352
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

9,477 results
Results by year
Filters applied: . Clear all
Page 1
Drug development in Alzheimer's disease: the path to 2025.
Cummings J, et al. Alzheimers Res Ther 2016 - Review. PMID 27646601 Free PMC article.
The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. ...
The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public he …
Heterogeneity of Alzheimer's disease: consequence for drug trials?
Devi G and Scheltens P. Alzheimers Res Ther 2018. PMID 30567585 Free PMC article.
However, Alzheimer's disease drug trials do not account for the heterogeneity of the disease in trial design, impeding development of effective drugs. ...Approaching Alzheimer's disease as a heterogenous disorder will likely improve yield in the search for effective treatments for the condition....
However, Alzheimer's disease drug trials do not account for the heterogeneity of the disease in trial design, impeding development of …
Alzheimer dementia: Starting, stopping drug therapy.
Kim LD and Factora RM. Cleve Clin J Med 2018 - Review. PMID 29522388 Free article.
Alzheimer disease is the most common type of dementia. Two classes of cognition-enhancing drugs are approved to treat the symptoms, and both have provided modest benefit in clinical trials. Psychotropic drugs are sometimes used off-label to treat behavioral symptoms of Alzheimer disease. All these medications should be continuously evaluated for clinical efficacy and, when appropriate, discontinued if the primary benefit--preservation of cognitive and functional status and a reduction in behaviors associated with dementia--is no longer being achieved....
Alzheimer disease is the most common type of dementia. Two classes of cognition-enhancing drugs are approved to treat the symptoms, a
[Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
Hausner L and Frölich L. Dtsch Med Wochenschr 2019. PMID 30703832 German.
In moderate to severe Alzheimer's dementia, the NMDA-receptor-antagonist Memantin is indicated.Lewy body dementia is treated as Alzheimer's disease; for Parkinson's dementia, there is a separate indication for rivastigmin. ...In current clinical trials, mild cognitive impairment due to Alzheimer's disease is targeted as the most meaningful study population.Implications for practice: At present, there just is symptomatic anti-dementive drug therapy available for Alzheimer's dementia, Parkinson's dementia and Lewy body dementia. ...
In moderate to severe Alzheimer's dementia, the NMDA-receptor-antagonist Memantin is indicated.Lewy body dementia is treated as Al
The Role of Biomarkers in Alzheimer's Disease Drug Development.
Cummings J. Adv Exp Med Biol 2019 - Review. PMID 30747416 Free PMC article.
Biomarkers have a key role in Alzheimer's disease (AD) drug development. Biomarkers can assist in diagnosis, demonstrate target engagement, support disease modification, and monitor for safety. ...
Biomarkers have a key role in Alzheimer's disease (AD) drug development. Biomarkers can assist in diagnosis, demonstrate target engag …
[Drug Repositioning for Alzheimer's Disease].
Ihara M and Saito S. Brain Nerve 2019. PMID 31506398 Japanese.
To date, all clinical trials of disease-modifying drugs for Alzheimer's disease (AD) have been unsuccessful, making investments into AD drug development very risky despite the high unmet need. ...
To date, all clinical trials of disease-modifying drugs for Alzheimer's disease (AD) have been unsuccessful, making investments into …
Drug repositioning in Alzheimer's disease.
Corbett A, et al. Front Biosci (Schol Ed) 2015 - Review. PMID 25961694
Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer's Disease and dementia therapeutics. ...
Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer's Disease and demen …
Current opinion in Alzheimer's disease therapy by nanotechnology-based approaches.
Ansari SA, et al. Curr Opin Psychiatry 2017 - Review. PMID 28009724
The current review covers the most recent findings of Alzheimer's disease (AD) therapeutics based on nanoscience and technology. ...
The current review covers the most recent findings of Alzheimer's disease (AD) therapeutics based on nanoscience and technology. ...
9,477 results
Jump to page
Feedback